Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma
J Am Coll Surg
.
2020 Nov;231(5):554-556.
doi: 10.1016/j.jamcollsurg.2020.08.751.
Authors
Vernon K Sondak
1
,
Jane L Messina
1
,
Ahmad A Tarhini
1
Affiliation
1
Tampa, FL.
PMID:
33491653
DOI:
10.1016/j.jamcollsurg.2020.08.751
No abstract available
Publication types
Comment
MeSH terms
Cost-Benefit Analysis
Gene Expression Profiling
Humans
Melanoma* / therapy
Patient Selection
Skin Neoplasms* / therapy